Oxurion Concludes Preclinical Discussions, Focuses on Strategic Clinical Integration

On November 3, 2025, Oxurion NV, headquartered in Leuven, Belgium, announced the end of its discussions concerning the acquisition of a preclinical microbiology services company. After careful evaluation, Oxurion determined that necessary conditions for the transaction weren't met, displaying its commitment to strategic and financial discipline within its growth plan.

Nevertheless, Oxurion continues its transaction with a clinical operations and regulatory affairs specialist, currently in the due diligence phase. This transaction seeks to enhance Oxurion's capabilities in clinical trial management, aiming for operational synergy.

Oxurion maintains its pursuit of building an integrated network of European pharmaceutical subcontractors, focusing on comprehensive service provision. An exclusivity agreement remains until December 31, 2025, with the target company refraining from third-party negotiations.